NasdaqCM:VKTXBiotechs
Should Viking’s VK2735 Obesity Data Debut in Europe Require Action From Viking Therapeutics (VKTX) Investors?
Viking Therapeutics, Inc. has announced it will present two posters on its VK2735 obesity program at the 33rd European Congress on Obesity in Istanbul on May 12–15, 2026, including Phase 2 VENTURE-Oral efficacy and safety data and Phase 3 VANQUISH-1 trial design details.
This upcoming disclosure of oral and subcutaneous VK2735 data highlights Viking’s push to compete with existing GLP-1 and dual GLP-1/GIP obesity treatments such as semaglutide and tirzepatide.
We’ll now examine how the...